Teva Pharmaceuticals, a US affiliate of Israel-based pharmaceutical company Teva Pharmaceutical Industries Ltd (NYSE:TEVA) (TASE:TEVA), and French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) reported on Thursday that patient enrolment in the Phase 2b RELIEVE UCCD trial for anti-TL1A drug duvakitug in moderate-to-severe ulcerative colitis (UC) and Crohn's disease (CD) has completed early due to a significant acceleration in patient recruitment.
Topline results for both UC and CD are now expected in Q4 2024, with detailed results in 2025.
Teva and Sanofi partnered to co-develop and co-commercialise duvakitug in October 2023. Under the terms of the agreement, Teva received USD500m upfront and may receive up to USD1bn in milestones. The two companies share development costs and net profits in major markets, with royalty arrangements in other markets. Sanofi will lead Phase 3 development.
Teva will lead commercialisation of the product in Europe, Israel and specified other countries, while Sanofi will lead commercialisation in North America, Japan other parts of Asia and the rest of the world.
Indivior updates on Aelis Farma's Phase 2B study of AEF0117 for Cannabis Use Disorder
Vesper Bio announces positive Phase I results for FTD treatment
Empower Pharmacy names new president
Innovent's IBI363 receives US FDA Fast Track Designation
Valneva and Pfizer report positive Phase 2 booster results for Lyme disease vaccine
Grit Biotechnology's GT201 receives US FDA IND approval
Cereno Scientific doses first patient in Expanded Access Program for PAH
Medicilon USA begins operations at second R&D centre in Massachusetts
CS Genetics names new chief operating officer and chief scientific officer
Expanse Medical names new chief executive officer and FlowPhysix board member